TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07704866: An Open-Label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FG-M108 Injection in Combination With FG-B901 Injection in Patients With Unresectab

Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07704866 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07704866 Rescue Dossier →